Table 1 Correlation between the clinicopathological factors and expression of miR-205-5p and ANGPT2 in endometriosis
From: miR-205-5p inhibits human endometriosis progression by targeting ANGPT2 in endometrial stromal cells
| Â | miR-205-5p expression | ANGPT2 expression | ||||
|---|---|---|---|---|---|---|
High | Low | P | High | Low | P | |
Patients (n) | 19 | 49 | Â | 45 | 23 | Â |
Age (years) | 31.26 ± 5.98 | 31.98 ± 6.36 | 0.67 | 32.18 ± 6.43 | 31.00 ± 5.85 | 0.464 |
Haemoglobin (g/L) | 113.89 ± 15.08 | 114.80 ± 18.00 | 0.85 | 113.98 ± 18.07 | 115.65 ± 15.44 | 0.706 |
Endometrial phase (%) | Â | |||||
 Proliferative phase | 78.95% | 83.67% |  | 82.22% | 82.61% |  |
 Secretive phase | 21.05% | 16.33% | 0.917 | 17.78% | 17.39% | 0.97 |
Dysmenorrhoea pain score (%) | ||||||
 Less than 4 points | 57.89% | 30.61% |  | 28.89% | 56.52% |  |
 More than 4 points | 42.11% | 69.39% | 0.038 | 71.11% | 43.48% | < 0.001 |
Chronic pelvic pain score (%) | ||||||
 Less than 4 points | 42.11% | 36.69% |  | 31.11% | 47.83% |  |
 More than 4 points | 57.89% | 65.31% | 0.57 | 68.89% | 52.17% | 0.18 |
 E2 (pmol/L) | 369.58 ± 355.63 | 296.55 ± 301.26 | 0.245 | 276.76 ± 279.00 | 395.61 ± 373.30 | 0.054 |
 CA-125 (kU/L) | 34.31 ± 21.27 | 109.55 ± 140.91 | 0.001 | 116.67 ± 144.86 | 33.47 ± 21.40 | < 0.001 |
Endometriosis score (%) | ||||||
 Less than 16 points | 68.42% | 38.78% |  | 35.56% | 69.57% |  |
 More than 16 points | 31.58% | 61.22% | 0.028 | 64.44% | 30.43% | 0.008 |